

-continued

(A) LENGTH: 30 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: other nucleic acid	
(iii) HYPOTHETICAL: NO	
(iv) ANTI-SENSE: YES	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	
CTGCAGGTTG GACCACTGGA TCCTGCCGAT	30
 (2) INFORMATION FOR SEQ ID NO:3:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 20 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: other nucleic acid	
(iii) HYPOTHETICAL: NO	
(iv) ANTI-SENSE: YES	
(ix) SEQUENCE DESCRIPTION: SEQ ID NO:3:	
TCCTTCGTTG CCGGTCCACA	20
 (2) INFORMATION FOR SEQ ID NO:4:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 20 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: other nucleic acid	
(iii) HYPOTHETICAL: NO	
(iv) ANTI-SENSE: NO	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:	
CGTCTCCGGA GTCCATCACA	20

What is claimed is:

1. A method of inhibiting expression of inducible nitric oxide synthase in a mammal system, comprising administering to said mammal system an amount of a tetracycline compound sufficient to inhibit inducible nitric oxide synthase expression in said mammal system.

2. The method according to claim 1, wherein the tetracycline compound has substantially no anti-microbial activity in said mammal system.

3. The method according to claim 1, wherein the tetracycline compound has metalloproteinase inhibitory activity.

4. The method according to claim 1, wherein the tetracycline compound is 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3), 6- α -deoxy-5-hydroxy-4-dedimethylaminotetracycline (CMT-8), 4-dedimethylaminotetracycline (CMT-1), doxycycline, or minocycline.

5. The method according to claim 1, wherein said mammal system is a mammal having a condition characterized by increased nitric oxide production.

6. The method according to claim 5, wherein said mammal has nitric oxide-dependent glomerular inflammation.

7. The method according to claim 5, wherein said mammal has osteoarthritis.

8. The method according to claim 1, wherein said method further comprises providing to said mammal system an anti-inflammatory amount of a steroidal or non-steroidal anti-inflammatory drug.

9. The method according to claim 1, wherein said mammal system is a mammal having a condition characterized by an abnormally high level of activity of inducible nitric oxide synthase.

10. The method according to claim 1, wherein said mammal system is an in vitro cellular system or an ex vivo tissue or organ system wherein a measured amount of nitric oxide production is indicative of expression of inducible nitric oxide synthase.

* * * * *